Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

Nashville Biosciences LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, and global DNA sequencing giant Illumina Inc.

Illumina & NashBio announce Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery: San Diego Friday, March 21, 2025, 10:00 Hrs [IST] Illumina ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks ... in patients with the genetic disorder neurofibromatosis type 1 (NF1), a rare genetic condition.

and a $4.2 billion deal with Seattle Genetics covering ADCs for breast cancer and other solid tumours. The deal-making activity signals Merck’s determination to stay at the forefront of cancer ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

The future of the life sciences industry hinges on AI and automation, driving innovation in drug discovery and addressing ...

Both supporters and critics praise Columbia University’s interim president for her openness. But will she stand up to Donald ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Exelixis, Inc.

In Ukraine, before the war, neurological care for children was provided by approximately 700 paediatric neurologists (one per 8400 children). The responsibilities of paediatric neurologists in Ukraine ...